CAR-T Therapy in Early Lines of R/R MM: Clinical Scenario Discussion and Key Takeaways
Panelists discuss successful collaborations between academic centers and community practices in the context of (chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma, key lessons learned in integrating CAR T therapy into the treatment landscape, and future plans for expanding CAR T therapy’s role in earlier lines of multiple myeloma treatment.
Video content above is prompted by the following:
- Can you share any examples of successful collaborations between your academic center and community practices in the context of CAR-T therapy for multiple myeloma?
- What are the most important lessons your institution has learned in the integration of CAR-T therapy into the multiple myeloma treatment landscape?
- Looking ahead, what are your institution’s plans or considerations for further expanding the role of CAR-T therapy into earlier lines of multiple myeloma treatment?
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
